Top Page
Fidia Spa
(FDA)
Fidia Spa (FDA) vs. iShares MSCI Italy ETF (EWI)
Fidia Spa Business Overview & Revenue Model
Fidia Spa Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.45M | 17.49M | 28.61M | 24.37M | 23.84M | 21.24M |
| Gross Profit | 16.05M | 12.97M | 19.13M | 1.45M | 15.53M | 13.68M |
| EBITDA | -4.05M | -7.66M | 667.00K | 7.63M | -888.00K | -3.37M |
| Net Income | -2.19M | -9.30M | -1.31M | 5.97M | -3.50M | -5.95M |
Balance Sheet | ||||||
| Total Assets | 25.83M | 28.30M | 32.17M | 32.13M | 40.47M | 38.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.67M | 1.67M | 3.17M | 4.87M | 5.27M | 4.85M |
| Total Debt | 1.23M | 1.01M | 11.44M | 8.26M | 11.68M | 14.56M |
| Total Liabilities | 21.72M | 25.35M | 28.74M | 4.55M | 42.21M | 37.80M |
| Stockholders Equity | 4.13M | 2.94M | 3.22M | 5.97M | -2.33M | -117.00K |
Cash Flow | ||||||
| Free Cash Flow | 1.10M | -4.45M | -5.31M | 495.00K | 498.00K | 3.27M |
| Operating Cash Flow | 1.27M | -4.34M | -4.84M | 793.00K | 584.00K | 3.77M |
| Investing Cash Flow | 1.46M | -47.00K | -357.00K | -231.00K | -57.00K | -181.00K |
| Financing Cash Flow | -1.28M | 2.44M | 3.43M | 747.00K | -1.09M | -1.47M |
Fidia Spa Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €157.10M | 37.32 | 3.03% | 4.22% | 3.13% | -57.84% | |
54 Neutral | €104.70M | -170.00 | 6.78% | ― | -1.90% | 91.60% | |
52 Neutral | €71.65M | -3.26 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | €3.72M | -0.03 | -51.46% | ― | -27.40% | 82.08% |
Fidia Spa Corporate Events
Fidia S.p.A. has issued its November 2025 monthly financial disclosure under CONSOB’s special transparency regime, providing updated information on the group’s net financial position, overdue debt by category, and changes in related-party relationships, while noting that the figures are prepared under IFRS and remain unaudited. The company also outlines the status and regulatory treatment of its structured financing arrangements, including a fully converted 2022–2024 convertible bond program and the ongoing 2025 convertible bond with warrants reserved to Global Growth Holding Limited, for which CONSOB now requires detailed, recurring disclosure on subscription, conversion activity, costs and the role of these instruments in supporting Fidia’s industrial and financial plans, underscoring the level of regulatory scrutiny and the importance of these financings to the company’s capital structure and continuity of operations.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia has increased its fully paid‑up share capital to €9,847,761.90 following the conversion of €500,000 worth of outstanding convertible bonds into 5,000,000 new ordinary shares. As a result, the total number of ordinary shares admitted to trading on Euronext Milan has risen from 25,298,485 to 30,298,485, and the updated share capital structure has been duly filed with the Turin Companies Register, signalling a completed step in the company’s planned capital strengthening and a resulting dilution for existing shareholders but improved equity position for the group.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia has completed a key step in its financing plan with Global Growth Holding Limited (GGHL), issuing and having fully subscribed a tranche of 50 reserved convertible bonds with attached warrants for a nominal €500,000, alongside 1,250,000 new warrants exercisable over 60 months at an adjusted price of €0.20 per share. On the same day, GGHL requested and obtained the full conversion of these bonds at €0.10 per share, resulting in the issue of 5,000,000 new Fidia shares admitted directly to trading, bringing the company’s share capital to €9,847,761.90 and total shares outstanding to 30,298,485; with this transaction the €4 million POC convertible bond program and its related capital increase are now fully subscribed and converted, strengthening Fidia’s equity base and potentially diluting existing shareholders while supporting its capital structure for future operations.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced a change in its share capital following the conversion of outstanding convertible bonds into ordinary shares over several transactions carried out between late November and mid-December 2025. As a result, the company’s fully subscribed and paid-in share capital has risen by €750,000 to €9,347,761.90, while the number of ordinary shares has increased from 18,977,312 to 25,298,485, all admitted to trading on Euronext Milan. The updated Articles of Association and the statutory statement certifying the progressive execution of the capital increase have been filed with the Companies Register of Turin, formalizing the strengthened equity structure and expanding the free float for investors.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the conversion of 8 POC bonds into 800,000 new shares, following a request from Global Growth Holding Limited. This conversion, priced at Euro 0.10 per share, results in a capital increase of Euro 80,000, bringing the total share capital to Euro 9,347,761.90 and the total number of shares to 25,298,485. This move signifies a strategic financial adjustment, potentially impacting the company’s market positioning and shareholder value.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of 7 bonds into 700,000 new shares by Global Growth Holding Limited, part of a convertible bond loan with warrants. This conversion increases Fidia’s share capital by Euro 70,000, bringing the total number of shares to 24,498,485. The move reflects Fidia’s strategic financial maneuvers to bolster its market position and enhance shareholder value.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the publication of an information document regarding a significant transaction with related parties. This involves an investment agreement with Global Growth Holding Limited for a bond loan with warrants convertible into ordinary shares, amounting to a maximum of 5 million euros. This move is expected to impact Fidia’s financial structure and potentially enhance its market position.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of 10 bonds into 1,000,000 new shares by Global Growth Holding Limited, with a conversion price of Euro 0.10 per share. This conversion increases the company’s share capital by Euro 100,000, bringing the total number of shares to 23,798,485. The partial execution of the capital increase will be filed with the Turin Companies Register, reflecting the company’s strategic financial maneuvers to enhance its market position and shareholder value.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the conversion of 10 POC bonds into new shares, resulting in the issuance of 909,090 new shares to Global Growth Holding Limited. This conversion increases the company’s share capital by Euro 100,000, bringing the total number of shares to 22,798,485. The move reflects Fidia’s strategic financial management and is expected to enhance its market position by increasing liquidity and shareholder base.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced an Extraordinary Meeting on January 9, 2026, to discuss a financing operation involving the issuance of a convertible bond loan and warrants, aimed at raising up to 5 million euros. This move is intended to enhance the company’s capital structure and potentially impact its market positioning by involving Global Growth Holding Limited, with implications for shareholder voting rights and share capital adjustments.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has signed an investment agreement with Global Growth Holding Limited for a convertible bond loan cum warrant valued at 5 million Euros, aimed at supporting its financial restructuring and operational needs. This move follows previous agreements and is part of Fidia’s ongoing efforts to address financial challenges and continue its corporate restructuring process, indicating a strategic focus on stabilizing its financial position and enhancing shareholder value.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of 10 bonds into 769,230 new shares by Global Growth Holding Limited, as part of a convertible bond loan with warrants. This conversion increases the company’s share capital by Euro 100,000, bringing the total number of shares to 21,889,395. The move reflects Fidia’s ongoing financial strategies to strengthen its market position and potentially enhance shareholder value.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of five bonds into 357,142 new shares by Global Growth Holding Limited, as part of a convertible bond loan with warrants. This conversion increases Fidia’s share capital by Euro 50,000, bringing the total number of shares to 20,405,881. The move reflects Fidia’s ongoing capital restructuring efforts to enhance its market position and operational capacity.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the conversion of 5 bonds from its convertible bond loan with Global Growth Holding Limited, resulting in the issuance of 357,142 new shares at a conversion price of Euro 0.14 per share. This conversion increases the company’s share capital by Euro 50,000, bringing the total number of shares to 20,048,739. The move is part of a larger capital increase plan to service the bond loan, with implications for the company’s financial structure and market presence.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the issuance and subscription of a tranche of convertible bonds with attached warrants by Global Growth Holding Limited, amounting to a nominal value of Euro 750,000. Additionally, 10 bonds were converted into new Fidia shares, resulting in an increase in the company’s share capital and total number of shares. This financial maneuver is part of Fidia’s strategy to enhance its capital structure and market position, potentially impacting its stakeholders by increasing the liquidity and marketability of its shares.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
The Shareholders’ Meeting of Fidia S.p.A. approved the transfer of the company’s registered office from San Mauro Torinese to Turin, along with amendments to several articles of the company’s statute. These changes align with the Board of Directors’ proposals and are part of the company’s ongoing efforts to streamline operations and enhance its strategic positioning in the market.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has released its monthly financial update as of September 30, 2025, in compliance with regulatory requirements. The company has been actively involved in convertible bond loans and capital strengthening operations, which are crucial for its financial and industrial plans. The update includes details on financial positions, overdue debts, and changes in related party relations, reflecting the company’s ongoing efforts to maintain transparency and strategic alignment with its business objectives.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced a change in its share capital following the conversion of bonds into ordinary shares, resulting in an increase of 3,750,000 shares and a capital boost of 750,000 Euros. This move, which raises the total number of shares to 18,977,312, is expected to enhance Fidia’s market presence and operational capacity as it continues to trade on Euronext Milan.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the issuance and conversion of 75 bonds into new shares, increasing its share capital by Euro 750,000 to a total of Euro 8,597,761.90. This strategic move, involving Global Growth Holding Limited, enhances Fidia’s financial structure and market presence, potentially benefiting stakeholders by expanding its capital base and reinforcing its position in the industry.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the termination of employment with its CFO, Dr. Luca Carante, as part of a strategic move to strengthen its organizational structure. The company is actively seeking a new candidate for the CFO and Investor Relations Manager roles, with interim responsibilities being handled by the CEO and Chairman.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has terminated its relationship with Dr. Luca Carante, who held the positions of Group Chief Financial Officer and Investor Relations Manager. This decision is part of a strategic move by the company’s top management to strengthen its organizational structure. In the interim, the CEO and Chairman of the Board will assume these roles until a suitable replacement is found. The company has initiated a selection process to appoint a new CFO and Investor Relations Manager, ensuring compliance with statutory and regulatory requirements.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced a change in its share capital following the conversion of bonds into ordinary shares, resulting in an increase of the share capital by Euro 600,000.00. The total number of shares has risen from 12,452,385 to 15,227,312, all of which are traded on Euronext Milan. This adjustment reflects Fidia’s strategic financial maneuvering to enhance its market position and operational capacity.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of five bonds into 277,777 new shares at a price of Euro 0.18 per share, as part of a convertible bond loan with GGHL. This conversion increases the company’s share capital by Euro 50,000, bringing the total to Euro 7,847,761.90, and the total number of shares to 15,227,312. This move reflects Fidia’s ongoing financial strategies and its commitment to maintaining a strong market presence.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the conversion of five bonds into 277,777 new shares at a price of Euro 0.18 per share, as part of a convertible bond loan with GGHL. This conversion increases the company’s share capital by Euro 50,000, bringing the total number of shares to 14,949,535, and reflects ongoing strategic financial maneuvers to enhance its market position.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced that its Half-Year Financial Report as of June 30, 2025, includes a paragraph from Deloitte & Touche S.p.A. highlighting significant uncertainties regarding business continuity. This disclosure raises concerns about the company’s ongoing operations and could impact its market position and stakeholder confidence.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.